Current treatment and epidemiology of Clostridium difficile infections;Actualités épidémiologiques et thérapeutiques des infections à Clostridium difficile

Revue de Medecine Interne

Volumn 36, Issue 9, 2015, Pages 596-602

  Dinh, A ^a   Bouchand, F ^a   Le Monnier, A ^b,c  

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b SAINT JOSEPH HOSPITAL   (France)

^c University Paris Sud   (France)

Author keywords

Antimicrobial therapy; Clostridium difficile; Fecal microbiota transplantation; Fidaxomicine; Vancomycine

Indexed keywords

FIDAXOMICIN; IMMUNOGLOBULIN; METRONIDAZOLE; VANCOMYCIN; ANTIINFECTIVE AGENT; PROBIOTIC AGENT;

ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTERIAL VIRULENCE; CHELATION; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; DRUG EFFICACY; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; MEDICAL PROCEDURES; PREGNANT WOMAN; PUBLIC HEALTH PROBLEM; RECURRENCE RISK; RECURRENT DISEASE; RISK FACTOR; SHORT SURVEY; TOXIN CHELATION; TREATMENT FAILURE; ADULT; CHILD; CLOSTRIDIUM INFECTIONS; COLON RESECTION; FEMALE; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; PREGNANCY; PROCEDURES;

ADULT; ANTI-BACTERIAL AGENTS; CHILD; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLECTOMY; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; HUMANS; PREGNANCY; PROBIOTICS;

EID: 84940467328     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2015.02.003     Document Type: Short Survey

References (59)

1. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353:2442-2449.
2. Goorhuis A., Bakker D., Corver J., Debast S.B., Harmanus C., Notermans D.W., et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008, 47:1162-1170.
3. Kyne L., Warny M., Qamar A., Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000, 342:390-397.
4. Rupnik M., Wilcox M.H., Gerding D.N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009, 7:526-536.
5. Bignardi G.E. Risk factors for Clostridium difficile infection. J Hosp Infect 1998, 40:1-15.
6. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
7. Barbut F., Guery B., Eckert C. Comment traiter une infection digestive à Clostridium difficile en 2014 ?. Reanimation 2014, 23:284-297.
8. Kyne L., Warny M., Qamar A., Kelly C.P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001, 357:189-193.
9. Loo V.G., Bourgault A.M., Poirier L., Lamothe F., Michaud S., Turgeon N., et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011, 365:1693-1703.
10. Debast S.B., Bauer M.P., Kuijper E.J., European Society of Clinical Microbiology and Infectious Diseases European Society of Clinical Microbiology and Infectious Diseases (ESCMID): update of the treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2014, 20(Suppl. 2):S1-S26.
11. Gerding D.N. Global epidemiology of Clostridium difficile infection in 2010. Infect Control Hosp Epidemiol 2010, 31(Suppl. 1):S32-S34.
12. Bartlett J.G., Gerding D.N. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl. 1):S12-S18.
13. Lambert M.L., Mertens K., Ramboer I., Delmée M., Suetens C. Nation-wide prospective surveillance of Clostridium difficile infections in hospitals in Belgium, July 2007-June 2008. Euro Surveill 2009, 14:2-4.
14. Barbut F., Menuet D., Verachten M., Girou E. Comparison of the efficacy of a hydrogen peroxide dry-mist disinfection system and sodium hypochlorite solution for eradication of Clostridium difficile spores. Infect Control Hosp Epidemiol 2009, 30:507-514.
15. Dubberke E.R., Butler A.M., Reske K.A., Agniel D., Olsen M.A., D'Angelo G., et al. Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerging Infect Dis 2008, 14:1031-1038.
16. Kuijper E.J., Coignard B., Tüll P., ESCMID Study Group for Clostridium difficile, EU Member States, European Centre for Disease Prevention and Control Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006, 12(Suppl. 6):S2-S18.
17. Bauer M.P., Notermans D.W., Van Benthem B.H.B., Brazier J.S., Wilcox M.H., Rupnik M., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377:63-73.
18. Davies K.A., Longshaw C.M., Davis G.L., Bouza E., Barbut F., Barna Z., et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis 2014, 14:1208-1219.
19. Eckert C., Coignard B., Hebert M., Tarnaud C., Tessier C., Lemire A., et al. Clinical and microbiological features of Clostridium difficile infections in France: the ICD-RAISIN 2009 national survey. Med Mal Infect 2013, 43:67-74.
20. Gilca R, Fortin E, Hubert B, Frenette C, Gourdeau M. Surveillance des diarrhées associées à Clostridium difficile au Québec. Institut National De Santé Publique. Bilan du 17 aoÛt 2008 au 15 aoÛt 2009, 2009. [Accès au site le 09/10/2014]. http://www.inspq.qc.ca/pdf/publications/1064_cdifficile_17aout2008-15aout2009.pdf.
21. McDonald L.C., Owings M., Jernigan D.B. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerging Infect Dis 2006, 12:409-415.
22. Miller B.A., Chen L.F., Sexton D.J., Anderson D.J. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 2011, 32:387-390.
23. Pépin J., Valiquette L., Alary M.E., Villemure P., Pelletier A., Forget K., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171:466-472.
24. Pepin J., Alary M.E., Valiquette L., Raiche E., Ruel J., Fulop K., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005, 40:1591-1597.
25. Hall A.J., Curns A.T., McDonald L.C., Parashar U.D., Lopman B.A. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis 2012, 55:216-223.
26. Musher D.M., Aslam S., Logan N., Nallacheru S., Bhaila I., Borchert F., et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005, 40:1586-1590.
27. Aslam S., Hamill R.J., Musher D.M. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005, 5:549-557.
28. e Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse 2012.
29. Zilberberg M.D., Tillotson G.S., McDonald C. Clostridium difficile infections among hospitalized children, United States, 1997-2006. Emerg Infect Dis 2010, 16:604-609.
30. He M., Miyajima F., Roberts P., Ellison L., Pickard D.J., Martin M.J., et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013, 45:109-113.
31. Dial S., Delaney J.A., Barkun A.N., Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294:2989-2995.
32. Dial S., Delaney J.A., Schneider V., Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 2006, 175:745-748.
33. Khanna S., Pardi D.S., Aronson S.L., Kammer P.P., Orenstein R., St Sauver J.L., et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 2012, 107:89-95.
34. Chitnis A.S., Holzbauer S.M., Belflower R.M., Winston L.G., Bamberg W.M., Lyons C., et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med 2013, 173:1359-1367.
35. Beaugerie L., Pardi D.S. Review article: drug-induced microscopic colitis - proposal for a scoring system and review of the literature. Aliment Pharmacol Ther 2005, 22:277-284.
36. Shannon-Lowe J., Matheson N.J., Cooke F.J., Aliyu S.H. Prevention and medical management of Clostridium difficile infection. BMJ 2010, 340:1296.
37. Wenisch J.M., Schmid D., Kuo H.W., Allerberger F., Michl V., Tesik P., et al. Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection. Antimicrob Agents Chemother 2012, 56:1974-1978.
38. Zar F.A., Bakkanagari S.R., Moorthi K.M., Davis M.B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007, 45:302-307.
39. Johnson S., Louie T.J., Gerding D.N., Cornely O.A., Chasan-Taber S., Fitts D., et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014, 59:345-354.
40. Al-Nassir W.N., Sethi A.K., Li Y., Pultz M.J., Riggs M.M., Donskey C.J. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008, 52:2403-2406.
41. Nerandzic M.M., Mullane K., Miller M.A., Babakhani F., Donskey C.J. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 2012, 55(Suppl. 2):S121-S126.
42. Louie T.J., Miller M.A., Mullane K.M., Weiss K., Lentnek A., Golan Y., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011, 364:422-431.
43. Cornely O.A., Crook D.W., Esposito R., Poirier A., Somero M.S., Weiss K., et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012, 12:281-289.
44. Cornely O.A., Miller M.A., Fantin B., Mullane K., Kean Y., Gorbach S. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol 2013, 31:2493-2499.
45. Gough E., Shaikh H., Manges A.R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011, 53:994-1002.
46. Van Nood E., Vrieze A., Nieuwdorp M., Fuentes S., Zoetendal E.G., de Vos W.M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013, 368:407-415.
47. ANSM La transplantation de microbiote fécal et son encadrement dans les essais cliniques 2014, [http://ansm.sante.fr/var/ansm_site/storage/original/application/5e5e01018303790194275ded0e02353c.pdf. Accès au site le 09/10/2014].
48. Besselink M.G., van Santvoort H.C., Buskens E., Boermeester M.A., van Goor H., Timmerman H.M., et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:651-659.
49. Musher D.M., Logan N., Bressler A.M., Johnson D.P., Rossignol J.F. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009, 48:e41-e46.
50. De Lalla F., Nicolin R., Rinaldi E., Scarpellini P., Rigoli R., Manfrin V., et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992, 36:2192-2196.
51. Wenisch C., Parschalk B., Hasenhündl M., Hirschl A.M., Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996, 22:813-818.
52. Herpers B.L., Vlaminckx B., Burkhardt O., Blom H., Biemond-Moeniralam H.S., Hornef M., et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009, 48:1732-1735.
53. Kopterides P., Papageorgiou C., Antoniadou A., Papadomichelakis E., Tsangaris I., Dimopoulou I., et al. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth Intensive Care 2010, 38:755-758.
54. Johnson S., Schriever C., Galang M., Kelly C.P., Gerding D.N. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007, 44:846-848.
55. Garey K.W., Ghantoji S.S., Shah D.N., Habib M., Arora V., Jiang Z.D., et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011, 66:2850-2855.
56. Lowy I., Molrine D.C., Leav B.A., Blair B.M., Baxter R., Gerding D.N., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010, 362:197-205.
57. Clinical trial gov Ig ICD - A Study of MK-3415, MK-6072, and MK-3415A in participants receiving antibiotic therapy for Clostridium Difficile infection, 2010. [Accès au site le 09/10/2014]. http://clinicaltrials.gov/show/NCT01241552.
58. Sougioultzis S., Kyne L., Drudy D., Keates S., Maroo S., Pothoulakis C., et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005, 128:764-770.
59. Maîtrise de la diffusion des ICD dans les établissements de santé français. Avis du Haut Conseil de la santé publique relatif à la maîtrise de la diffusion des infections à Clostridium difficile dans les établissements de santé français 2008, [http://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?clefr=32. Accès au site le 09/10/2014].